Baseline and dynamic changes in skeletal muscle mass as predictive biomarkers in patients with metastatic renal cell carcinoma treated with Nivolumab
Pre-treatment low muscle mass and muscle mass decline during immunotherapy were independently associated with inferior survival and treatment response in mRCC patients receiving Nivolumab. CT-based muscle mass assessment may serve as an imaging-based prognostic biomarker in this population.
Authors
- Murathan Köksal (ORCID: https://orcid.org/0000-0002-5936-2925)
- Bünyamin Ece (ORCID: https://orcid.org/0000-0001-6288-8410)
- Omer F. Kuzu (ORCID: https://orcid.org/0000-0001-8715-4800)
- Efnan Algın (ORCID: https://orcid.org/0000-0002-8917-9267)
- Yusuf Açıkgöz (ORCID: https://orcid.org/0000-0002-0360-7938)
- Mustafa Koyun (ORCID: https://orcid.org/0000-0002-9811-4385)
- Erdem Özkan (ORCID: https://orcid.org/0000-0001-8120-7051)
Institutions
- Bilkent University (TR)
- State Hospital (GB)
- Memorial Ankara Hospital (TR)
- Başkent University Hospital (TR)
- Lokman Hekim Üniversitesi (TR)
- Kastamonu University (TR)
Publication Details
- Journal
- Radiology and Oncology
- Published
- 2025-12-01
- DOI
- https://doi.org/10.2478/raon-2025-0065
- Primary Topic
- Nutrition and Health in Aging
- Type
- article
- Field-Weighted Citation Impact
- 0.00